A Phase 2 interventional study of sapablursen in Beta Thalassemia Intermedia, sponsored by Ionis Pharmaceuticals, Inc.. Terminated at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in beta-Thalassemia with a site in Thailand — 2 open to participants now, 6 under way, 3 of them phase 3. beta-Thalassemia · Thailand.
Among the 24 studies in beta-Thalassemia with a site in Thailand, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 2, and was the 19th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →2 of the 24 studies in beta-Thalassemia with a site in Thailand are open now. Recruiting first, the newest first:
Celgene · Sites in Thailand, United States, China and 6 more countries
Ages 6–17
Celgene · Sites in Thailand, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 5
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 30 across the 22 interventional studies, 83 across the 2 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 24 have an industry lead sponsor. The 10 most frequent:
Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.
Ionis Pharmaceuticals, Inc. has 1 study filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
1 of the studies in beta-Thalassemia with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in beta-Thalassemia with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose was to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of sapablursen administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.
This was a multi-center, randomized, open-label study in up to 29 participants. The duration of participation for each subject in the study was approximately 29 months and included an approximately 2-month screening period, a 24-month treatment period, and a 3-month post-treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with or recent exposure to another drug, biological agent, antisense oligonucleotide (ASO), small interfering ribonucleic acid (siRNA), or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; or treatment with or exposure to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects initially received 30 mg/0.3 mL of sapablursen by (subcutaneous) SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks.
Drug: sapablursen
Subjects initially received 50 mg/0.5 mL of sapablursen by SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks
Drug: sapablursen
Subjects initially received 80 mg/0.8 mL of sapablursen by SC injection once every four weeks up to Week 105. After the protocol Amendment 2 the dose was increased to a maximum of 160 mg once every 4 weeks.
Drug: sapablursen
sapablursen administered subcutaneously
Also known as: ISIS 702843, IONIS TMPRSS6-LRx
Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27
Blood hemoglobin
Time frame: Baseline and Week 27
Percentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 53
Blood hemoglobin
Time frame: Week 53
Percentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 53
Liver iron content
Time frame: Week 53
Participants were enrolled in the study at 15 investigative sites in Australia, Greece, Lebanon, Thailand, and Turkey from 24 September 2020 to 28 March 2023.
| Milestone | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| Started | 6 | 6 | 17 |
| Completed | 1 | 1 | 2 |
| Not completed | 5 | 5 | 15 |
| Withdrew: Early treatment termination | 5 | 5 | 15 |
Blood hemoglobin
| percentage of participants | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| Percentage of Participants With a ≥1.0 Grams Per Deciliter (g/dL) Increase From Baseline in Hemoglobin (Hb) at Week 27 | 0 (0.0 to 45.9) | 0 (0.0 to 45.9) | 6.7 (0.2 to 31.9) |
Blood hemoglobin
| percentage of participants | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| Percentage of Participants With a ≥1.5 g/dL Increase From Baseline in Hb at Week 53 | 0 (0.0 to 45.9) | 0 (0.0 to 45.9) | 0 (0.0 to 23.2) |
Liver iron content
| percentage of participants | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| Percentage of Participants With a ≥1.0 Milligrams of Iron Per Grams of Dry Weight of Liver (mg Fe/g) Decrease From Baseline in Liver Iron Concentration (LIC) at Week 53 | 33.3 (4.3 to 77.7) | 50.0 (11.8 to 88.2) | 28.6 (8.4 to 58.1) |
Collected over From signing of informed consent to early termination (up to 733 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Sapablursen | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort B: Sapablursen | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort C: Sapablursen | 0/17 (0%) | 1/17 (5.9%) | 14/17 (82.4%) |
| Event | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| Forearm FractureInjury, poisoning and procedural complications | 0/6 | 1/6 | 0/17 |
| COVID-19Infections and infestations | 0/6 | 1/6 | 0/17 |
| PneumoniaInfections and infestations | 0/6 | 1/6 | 0/17 |
| Portal vein thrombosisHepatobiliary disorders | 0/6 | 0/6 | 1/17 |
| Event | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen |
|---|---|---|---|
| FatigueGeneral disorders | 4/6 | 1/6 | 1/17 |
| COVID-19Infections and infestations | 3/6 | 0/6 | 11/17 |
| Injection Site RashGeneral disorders | 0/6 | 2/6 | 0/17 |
| Vaccination Site PainGeneral disorders | 2/6 | 1/6 | 1/17 |
| HeadacheNervous system disorders | 0/6 | 2/6 | 2/17 |
| Abdominal Pain UpperGastrointestinal disorders | 1/6 | 2/6 | 0/17 |
| Abdominal DistensionGastrointestinal disorders | 0/6 | 2/6 | 0/17 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/6 | 1/6 | 3/17 |
| Back PainMusculoskeletal and connective tissue disorders | 1/6 | 2/6 | 2/17 |
| InfluenzaInfections and infestations | 2/6 | 2/6 | 1/17 |
| Age, Continuous(years) | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen | Total |
|---|---|---|---|---|
| Mean | 35.0 ± 12.12 | 31.7 ± 10.44 | 32.0 ± 10.88 | 32.6 ± 10.72 |
| Sex: Female, Male(Participants) | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 10 | 18 |
| Male | 2 | 2 | 7 | 11 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen | Total |
|---|---|---|---|---|
| Race — White | 3 | 5 | 9 | 17 |
| Race — Asian | 3 | 1 | 8 | 12 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Sapablursen | Cohort B: Sapablursen | Cohort C: Sapablursen | Total |
|---|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 6 | 6 | 17 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Mar 2023, 30 months.
Results were first posted in Feb 2025, 1 year 10 months after primary completion. A results delay was requested in Feb 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapablursen